A phase 1 study of entinostat in combination with atezolizumab, carboplatin, and etoposide in previously untreated extensive-stage small cell lung cancer

UVA Tracking #
HSR210064
Principal Investigator
Ryan Gentzler
Contact
Marietta Hockenberry
Contact Email
Contact Phone
434.297.7784
Official Trial Title
A Phase 1 Study of Entinostat in Combination with Atezolizumab/Carboplatin/Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer
Study Description

The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults ages 18 and over, and have small cell lung cancer. The purpose of this study to evaluate an investigational drug (entinostat) at varying doses in combination with chemotherapy drugs (atezolizumab, carboplatin, and etoposide) in patients with small cell lung cancer. The effects of the investigational drug will be evaluated for this study.

Participation includes a screening period, 3 week cycles of treatment for 1 year, with a longer term follow-up via a clinic visit or a phone call to keep track of how you’re doing. You may remain on the study as long as the treatment is still helping your disease. Study specific test will be provided at no cost to you.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT04631029

Compensation

You will receive $50 per study visit. The maximum amount you will receive for participating in this study is up to $1000.